Evidence map›Paper›PMID 41562939›Full record

ArticleMedical sciences (Basel, Switzerland)2026

Do Socio-Economic Determinants Influence DPYD Testing? A Real-World Study of 1478 Cancer Patients Receiving Fluoropyrimidine Chemotherapy.

Bahaaeldin Baraka, Navin Mathiyalagan, Maryam Al-Ani, Gaurav Mohindru, Torran Semple, Hrushikesh Divyateja, Grazziela Figueredo, Philip Quinlan, Guruprasad Padur Aithal, Srinivasan Madhusudan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical sciences (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bahaaeldin BarakaDepartment of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Navin MathiyalaganDepartment of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.ORCID 0009-0006-5744-9820
Maryam Al-AniDepartment of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Gaurav MohindruDepartment of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Torran SempleDepartment of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.
Hrushikesh DivyatejaDepartment of Chemical Pathology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Grazziela FigueredoDepartment of Computer Science, University of Nottingham, Nottingham NG8 1BB, UK.ORCID 0000-0003-4094-7680
Philip QuinlanHealth Informatics, NIHR Nottingham Biomedical Research Centre, Nottingham NG7 2UH, UK.ORCID 0000-0002-3012-6646
Guruprasad Padur AithalNIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, The University of Nottingham, Nottingham NG5 1PB, UK.ORCID 0000-0003-3924-4830
Srinivasan MadhusudanDepartment of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.ORCID 0000-0002-5354-5480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Dihydrouracil Dehydrogenase (NADP)NeoplasmsAgedAntimetabolites, AntineoplasticCapecitabineFemaleFluorouracilHumansMaleMiddle AgedSocioeconomic FactorsTegafurAntimetabolites, AntineoplasticCapecitabineDihydrouracil Dehydrogenase (NADP)FluorouracilTegafur5-fluorouracilcapecitabineDPYDreal-world data

Identifiers

PMID41562939
PMCPMC12821686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.